Home › Sequella Acquires Exclusive Worldwide Rights To Pfizer's Sutezolid, Currently In Clinical Development For Tuberculosis
 

Keywords :   


Sequella Acquires Exclusive Worldwide Rights To Pfizer's Sutezolid, Currently In Clinical Development For Tuberculosis

2013-07-17 04:00:00| drugdiscoveryonline Home Page

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, recently announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB)

Tags: rights development worldwide exclusive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Ahlstroms Climate Targets Validated by SBTi
07.11Mativ Reports Third Quarter Results
07.11Lawsuit over FDA's regulatory approval process for carbadox dismissed
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
More »